Sylke Inc launched SYLKE, a dressing made of pure hypoallergenic silk fibroin. SYLKE is designed to enhance healing across surgical wounds and to reduce complications and infections which can lead to poor scarring outcomes. Based on head-to-head data published today in the Aesthetic Surgery Journal (ASJ) Open Forum, SYLKE adhesive wound closure prototype outperformed DERMABOND PRINEO (p<0.001) across all measures, significantly reducing the incidence of medical adhesive-related skin injuries (MARSIs). The study was published in collaboration with The Johns Hopkins University School of Medicine and the University of California San Diego.
In a head-to-head clinical trial, the SYLKE prototype significantly outperformed DERMABOND PRINEO (p<0.001) across all measures, including: skin discomfort (4% vs. 64%), ACD including rash, itching and erythema (irritated, red skin) (0% vs. 52%), need for topical steroids or antibiotics for ACD and SSIs (0% vs. 52%), and dressing removal time (47 seconds vs. 1 minute and 39 seconds). SYLKE and DERMABOND PRINEO were evaluated in abdominoplasty (tummy tuck), body lift, breast reduction and mastopexy (breast lift) procedures.
A head-to-head comparison (n=50) of the SYLKE prototype versus the 3M Steri-Strip Skin Closure device will be published in spring 2024 adding to the growing body of evidence supporting the safety and efficacy of SYLKE. Multispecialty studies using SYLKE are in the planning stages at Johns Hopkins this fall.
SYLKE is commercially available and can be purchased over-the-counter by healthcare professionals and the general public through www.sylke.com. Five-unit introduction boxes will be launched at the cost of $115/strip — up to 32 percent less than a current standard of care — with volume discounts for large-scale buyers, such as hospital systems and clinics.
